PTC Therapeutics To Present Clinical And Real-World Evidence On Translarna At The Annual Congress Of The World Muscle Society
PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that recent clinical trial and real-world evidence on the efficacy and safety of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular